CALR and neoplasm: Notably, blocking CRT exposure on anthracycline-treated tumor cells can markedly reduce DC-mediated cross-presentation and anti-tumor immunity [90,91,92] while supplying endogenous CRT to dying tumor cells that cannot display endogenous CRT enhanced their immunogenicity [93], suggesting that CRT acts dominantly, over PS-mediated immunosuppression, and appears to be capable to unmask aforementioned tolerogenic signals on apoptotic cells.